Medscape1d
FDA OKs Guselkumab for Crohn’s Disease
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
MedPage Today on MSN5d
FDA Expands Guselkumab Approval to Crohn's Disease
The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
The American Journal of Managed Care4d
FDA Approves Guselkumab for Adult Patients With Crohn Disease
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
FDA approves Tremfya for active Crohn's disease in adults
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
MPR1d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
Wyoming Tribune Eagle1d
FDA Approves Tremfya for Active Crohn Disease in Adults
The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...
GlobalData on MSN4d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...
Fierce Pharma5d
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...